The Effectiveness of Tecar Therapy in Management of Calf Muscle Strain Injuries (MS)

April 25, 2026 updated by: Nabil Mahmoud Ismail Abdel-Aal, Cairo University
this study will be conducted to investigate the effect of TECAR Therapy on quality of landing, healing and Function in patient with Calf Muscle Strain.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Calf muscle strain is one of the most common muscle injuries in high-performance athletes and contributes to substantial player downtime because of its high mean time to return to sport and occurrence during critical periods in the competitive season. Published reports on lower-body muscle strain have provided frequent updates on the rehabilitation of high-profile muscle groups, such as the hamstring muscles, and improvements to calf strain management are seldom discussed despite the prevalence of these injuries in competitive sports. In this article, we discuss the diagnosis, treatment, outcomes, risk factors, and prevention of calf muscle strain in athletes.Transfer of Electricity-Capacitive and Resistive (Tecar) therapy is considered a special form of energy that uses frequencies between 300 KHz and 1 MHz and is characterized as a non-invasive high-frequency energy that awakens the body's natural ability to self-regenerate. Thus, it promotes the natural physiological processes of the tissue metabolically, transferring energy without introducing radiation from the external environment. TECAR therapy stands out as a promising yet underexplored modality. Its mechanism of action-utilizing both capacitive and resistive energy transfer-suggests a novel approach to addressing musculoskeletal injuries and pain. While preliminary studies and clinical applications hint at its potential advantages, such as improved tissue healing and pain relief, a comprehensive evaluation of the existing research is necessary to fully understand the role of TECAR therapy in rehabilitation

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged between 16-39 years of age.
  • not having suffered leg injuries in the past 6 months.
  • not having suffered a triceps sural rupture in the past two years.
  • be diagnosed with latent MTPs in the gastric-soleus complex through manual therapy in the dominant side.
  • Presence of Calf muscles Strain evaluated by Ultrasonography.
  • Athlete willing and able to participate in an exercise program safely.
  • The radiologist also assessed whether the tendon ends could be reduced in passive plantar flexion of the ankle joint with the knee extended.
  • Athlete BMI from 18.5 to 24.9 kg / m2

Exclusion Criteria:

  • connective tissue pathology.
  • lymphatic disorders (lymphadenopathy).
  • Skin injuries (open wounds, infection, psoriasis, tattoos, hematoma).
  • peripheral neuropathies.
  • previous fractures.
  • previous lower limb surgeries (in the past 12 months).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: TECAR therapy
Thirty patients will receive TECAR therapy combined with conventional treatment three times per week for 12 weeks.
Other: TECAR therapy
The TECAR intervention was administered to the calf muscle using the Zimmer devicein capacitive (CAP) mode for a duration of 20 min. The therapy was applied with the signal at a variable power with a maximum of 300 W. The frequency used was 500 kHz with an intensity of 40%. The intervention was standardized to a distal-to-proximal stroking rhythm with moderate pressure. For the TECAR intervention, the capacitive (CAP) mode at 500 kHz with 40% intensity and a maximum power of 300 W was chosen to optimize deep tissue heating and promote local blood flow and tissue recovery. The 20 min duration reflects protocols commonly used in therapeutic settings for muscle recovery and rehabilitation plus conventional therapy
Other: conventional treatment
the patients will receive stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee), eccentric exercises for calf muscles, plus plyometric exercises.
Active Comparator: conventional treatment
Thirty patients will receive conventional treatment three times per week for 12 weeks.
Other: conventional treatment
the patients will receive stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee), eccentric exercises for calf muscles, plus plyometric exercises.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
size of injury
Time Frame: up to 12 weeks
ultrasonography device will be used to assess size of injury
up to 12 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
landing error score system
Time Frame: up to 12 weeks
Landing Error Scoring System is a clinical tool used to assess jump-landing mechanics for the video from my jumb land aplication . the feet, ankle, knees, hip, trunk, shoulder, neck and head posture is assessed through the video. it is a 17-item . According to the performance sheet, the questions 1-15 are Yes/No questions that are rated as 0 or 1. The questions 16 are rated as 0, 1, and 2; 0 = soft, 1= average and 2= stiff. the question 17 are rated as 0,1,2; 0= excellent,1 average and 2= poor, so the total score ranges from zero to 19. A higher score indicates poor technique in landing from a jump; a lower score indicates better jump-landing technique. the score are categorized as excellent which less than 4, good score more than four and less than or equal 5, moderate score less than four and poor more than six
up to 12 weeks
jump height
Time Frame: up to 12 weeks
The vertical jump test was performed as a one-legged counter movement jump (CMJ). Starting position was in an upright position with the hands placed behind the back. The subjects quickly bent the knee as much as desired and then immediately jumped upward attempting to maximize the height jumped. The subjects performed three maximal approved trials for each leg, starting with the right and alternating between the right and the left leg. However, if the subject increased hop performance in all three jumps, additional jumps were performed until no increase was seen. The best jump height for each leg was used for data analysis.
up to 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 25, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 25, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
May 1, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 1, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 25, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • P.T.REC/012/006406

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings